CA
NZ
UK
AU
IND
US
…
Alterola Biotech, Inc., a pharmaceutical company, engages in the development of medicines manufactured from cannabinoid and cannabinoid-like molecules. It focuses on the development of regulated human and animal health pharmaceuticals and regulated food products; production of active pharmaceutical ingredients and food-grade ingredients; and formulation and drug delivery for improved bioavailability, solubility, and stability. Alterola Biotech, Inc. is based in Birkenhead, the United Kingdom.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Public information on Alterola Biotech Inc (ABTI) is scarce and the company's business description and filings are not readily available. Absent clear disclosures, long-term value would depend on typical biotech drivers such as successful clinical progress, regulatory approvals and commercialization or licensing deals, which may attract investors comfortable with high-risk, high-reward small-cap names.
Material risks include extremely low liquidity and wide bid-ask spreads on the Pink market, potential absence of audited financial statements, high dilution and financing risk, execution risk for product development and the possibility of regulatory action or delisting.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2024-03-31 | 2023-09-30 | 2023-03-31 | 2022-09-30 | 2022-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-03-31 | 2023-09-30 | 2023-03-31 | 2022-09-30 | 2022-03-31 |
| Income before tax | -2.37M | -1.70M | -1.70M | -6.47M | -6.47M |
| Net income | -2.37M | -1.54M | -1.54M | -6.47M | -6.47M |
| Selling general administrative | 2.08M | 1.65M | 1.65M | 4.04M | 4.04M |
| Ebit | - | -1.90M | -1.90M | -6.47M | -6.47M |
| Ebitda | - | -1.70M | -1.70M | -6.47M | -6.47M |
| Depreciation and amortization | - | 0.20M | 0.20M | -0.00M | -0.00M |
| Operating income | -2.11M | -1.90M | -1.90M | -6.47M | -6.47M |
| Other operating expenses | - | 1.70M | 1.70M | 6.47M | 6.47M |
| Interest expense | - | 0.20M | 0.20M | 0.00M | 0.00M |
| Tax provision | 0.00M | - | 0.00M | -0.15M | 0.00M |
| Income tax expense | - | -0.15M | -0.15M | -0.00M | -0.00M |
| Total revenue | 0.00M | - | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 2.11M | 1.70M | 1.70M | 6.47M | 6.47M |
| Total other income expense net | -0.27M | 0.20M | 0.20M | -0.00M | -0.00M |
| Net income from continuing ops | -2.37M | - | -2.07M | -1.54M | -6.47M |
| Net income applicable to common shares | - | - | - | -1.74M | - |
| Breakdown | 2024-03-31 | 2023-09-30 | 2023-03-31 | 2022-09-30 | 2022-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-03-31 | 2023-09-30 | 2023-03-31 | 2022-09-30 | 2022-03-31 |
| Total assets | 0.00M | 12.38M | 12.38M | 12.13M | 12.13M |
| Intangible assets | - | 12.14M | 12.14M | 12.00M | 12.00M |
| Other current assets | - | 0.24M | 0.24M | 0.01M | 0.01M |
| Total liab | 1.33M | 2.28M | 2.28M | 1.20M | 1.20M |
| Total stockholder equity | -1.33M | 10.10M | 10.10M | 10.93M | 10.93M |
| Other current liab | - | 1.52M | 0.90M | 0.49M | -0.05M |
| Common stock | - | 0.81M | 0.81M | 0.80M | 0.80M |
| Capital stock | 1.38M | - | 0.81M | 0.81M | 0.80M |
| Retained earnings | -12.42M | -9.58M | -9.58M | -7.97M | -7.97M |
| Cash | 0.00M | 0.01M | 0.01M | 0.06M | 0.06M |
| Total current liabilities | 1.33M | 2.13M | 2.13M | 1.20M | 1.20M |
| Current deferred revenue | - | -1.26M | -1.26M | - | - |
| Net debt | 0.14M | 1.41M | 1.41M | 0.10M | 0.10M |
| Short term debt | - | 1.26M | 1.26M | 0.16M | 0.16M |
| Short long term debt | 0.15M | - | 1.26M | 1.26M | 0.10M |
| Short long term debt total | - | 1.41M | 1.41M | 0.16M | 0.16M |
| Other stockholder equity | - | 18.86M | 18.86M | 18.08M | 18.08M |
| Total current assets | 0.00M | 0.24M | 0.24M | 0.13M | 0.13M |
| Net tangible assets | - | - | - | -2.04M | - |
| Net receivables | - | 0.04M | 0.04M | 0.05M | 0.05M |
| Long term debt | - | - | 0.15M | 0.15M | 0.16M |
| Inventory | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Accounts payable | - | 0.61M | 0.61M | 0.54M | 0.54M |
| Accumulated other comprehensive income | - | -0.06M | -0.06M | 0.01M | 0.01M |
| Non currrent assets other | - | -0.19M | -0.19M | 0.01M | - |
| Non current assets total | 0.00M | 12.14M | 12.14M | 12.00M | 12.00M |
| Breakdown | 2024-03-31 | 2023-09-30 | 2023-03-31 | 2022-09-30 | 2022-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-03-31 | 2023-09-30 | 2023-03-31 | 2022-09-30 | 2022-03-31 |
| Investments | - | - | -0.14M | -0.14M | 0.00M |
| Change to liabilities | - | - | - | 0.07M | - |
| Total cashflows from investing activities | - | - | -0.14M | -0.14M | - |
| Net borrowings | 1.47M | - | 1.15M | 1.16M | -0.38M |
| Total cash from financing activities | 1.47M | 1.21M | 1.21M | -0.01M | -0.01M |
| Change to operating activities | - | - | - | -0.12M | - |
| Net income | -2.37M | -1.74M | -1.74M | -6.47M | -6.47M |
| Change in cash | 0.02M | -0.05M | -0.05M | 0.06M | 0.06M |
| Begin period cash flow | 0.01M | 0.06M | 0.06M | 0.00M | 0.00M |
| End period cash flow | 0.00M | 0.01M | 0.01M | 0.06M | 0.06M |
| Total cash from operating activities | -1.45M | -1.04M | -1.04M | 0.04M | 0.04M |
| Issuance of capital stock | 0.00M | - | 0.05M | 0.05M | 0.37M |
| Depreciation | - | 0.14M | 0.14M | - | - |
| Change to inventory | -0.00M | - | 0.00M | -0.00M | -0.00M |
| Change to account receivables | - | - | - | -0.05M | -0.05M |
| Other cashflows from financing activities | - | 1.16M | 1.16M | -0.38M | -0.38M |
| Change to netincome | - | - | - | 0.75M | - |
| Capital expenditures | 0.00M | 0.14M | 0.14M | 0.14M | 0.00M |
| Change in working capital | 0.39M | -0.03M | -0.03M | 0.76M | 0.76M |
| Stock based compensation | - | 0.80M | 0.80M | 0.80M | 5.76M |
| Other non cash items | 0.54M | -0.01M | -0.01M | 5.76M | 5.76M |
| Free cash flow | -1.45M | -1.18M | -1.18M | 0.04M | 0.04M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| ABTI Alterola Biotech Inc |
- -% |
0.00 | - | - | - | 0.52 | -3.36 |
| MKKGY Merck KGaA ADR |
0.17 0.53% |
32.25 | 21.25 | 14.93 | 3.10 | 2.14 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
- -% |
161.82 | 24.86 | 15.11 | 3.13 | 1.98 | 18.89 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
-0.16 0.78% |
20.27 | - | 10.96 | 0.01 | 1.20 | 23.11 |
| TKPHF Takeda Pharmaceutical Co. Ltd. |
- -% |
41.22 | - | 10.66 | 0.01 | 1.16 | 23.11 |
Alterola Biotech, Inc., a pharmaceutical company, engages in the development of medicines manufactured from cannabinoid and cannabinoid-like molecules. It focuses on the development of regulated human and animal health pharmaceuticals and regulated food products; production of active pharmaceutical ingredients and food-grade ingredients; and formulation and drug delivery for improved bioavailability, solubility, and stability. Alterola Biotech, Inc. is based in Birkenhead, the United Kingdom.
| Name | Title | Year Born |
|---|---|---|
| Mr. Timothy Paul Rogers | Exec. Chairman & CFO | 1964 |
| Mr. Colin G. Stott B.Sc. | COO & Director | 1966 |
| Mr. Dominic Schiller | IP Counsel, Chief IP Officer & Director | 1965 |
| Mr. Hunter Land | VP of Translational Research & Director | 1985 |
| Mr. Seamus McAuley | Sec. & Director | 1976 |
| Mr. David Hitchcock O.B.E. | CEO & Director | 1963 |
| Mr. David John Hitchcock O.B.E. | Chief Executive Officer | 1963 |
| Mr. Nathan Thompson | CFO & Secretary | 1975 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+1.59%
Communication Services
+0.05%
Consumer Cyclical
+0.14%
Consumer Defensive
-0.43%
Energy
-0.03%
Financial Services
+0.19%
Financials
-0.35%
Healthcare
+1.05%
Industrials
+0.67%
Real Estate
-0.25%
Technology
+1.31%
Utilities
+0.32%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...